M. BEKSAÇ Et Al. , "Amplitude of Response, Early Mobilization (M) and Pre-Autologous Transplant (ASCT) Use of Bortezomib (V) and/or Thalidomide (T) Are Predictors of Longer Progression Free (PFS) and/or Overall Survival (OS) in Myeloma.," American Society of Hematology (ASH) 49th Annual Meeting and Exposition , vol.110, pp.5096, 2007
BEKSAÇ, M. Et Al. 2007. Amplitude of Response, Early Mobilization (M) and Pre-Autologous Transplant (ASCT) Use of Bortezomib (V) and/or Thalidomide (T) Are Predictors of Longer Progression Free (PFS) and/or Overall Survival (OS) in Myeloma.. American Society of Hematology (ASH) 49th Annual Meeting and Exposition , 5096.
BEKSAÇ, M., SOYDAN, E., ÖZKOCAMAN, V., TOPÇUOĞLU, P., EVRANOS, B., KIZIL, M., ... UĞUR BİLGİN, A.(2007). Amplitude of Response, Early Mobilization (M) and Pre-Autologous Transplant (ASCT) Use of Bortezomib (V) and/or Thalidomide (T) Are Predictors of Longer Progression Free (PFS) and/or Overall Survival (OS) in Myeloma. . American Society of Hematology (ASH) 49th Annual Meeting and Exposition (pp.5096).
BEKSAÇ, MERAL Et Al. "Amplitude of Response, Early Mobilization (M) and Pre-Autologous Transplant (ASCT) Use of Bortezomib (V) and/or Thalidomide (T) Are Predictors of Longer Progression Free (PFS) and/or Overall Survival (OS) in Myeloma.," American Society of Hematology (ASH) 49th Annual Meeting and Exposition, 2007
BEKSAÇ, MERAL Et Al. "Amplitude of Response, Early Mobilization (M) and Pre-Autologous Transplant (ASCT) Use of Bortezomib (V) and/or Thalidomide (T) Are Predictors of Longer Progression Free (PFS) and/or Overall Survival (OS) in Myeloma.." American Society of Hematology (ASH) 49th Annual Meeting and Exposition , pp.5096, 2007
BEKSAÇ, M. Et Al. (2007) . "Amplitude of Response, Early Mobilization (M) and Pre-Autologous Transplant (ASCT) Use of Bortezomib (V) and/or Thalidomide (T) Are Predictors of Longer Progression Free (PFS) and/or Overall Survival (OS) in Myeloma.." American Society of Hematology (ASH) 49th Annual Meeting and Exposition , p.5096.
@conferencepaper{conferencepaper, author={MERAL BEKSAÇ Et Al. }, title={Amplitude of Response, Early Mobilization (M) and Pre-Autologous Transplant (ASCT) Use of Bortezomib (V) and/or Thalidomide (T) Are Predictors of Longer Progression Free (PFS) and/or Overall Survival (OS) in Myeloma.}, congress name={American Society of Hematology (ASH) 49th Annual Meeting and Exposition}, city={}, country={}, year={2007}, pages={5096} }